← Leaderboards
Lalage Wakefield
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Top investigators on “Transforming Growth Factor Beta”
- J. Mark Cline · Wake Forest University$20,130,326
- Joan Massague · Sloan-Kettering Institute For Cancer Res$17,625,670
- Sumit K Chanda · Scripps Research Institute, The$14,981,889
- Martin M Matzuk · University Of Missouri-Columbia$14,528,941
- Rik M. Derynck · Children'S Hospital Los Angeles$13,841,953
- Xiao-Jing Wang · University Of California At Davis$13,685,362
Research focus
Transforming Growth Factor BetaCancer TherapyComplexPlayTumorigenesisTumorIn VivoTumor ProgressionTumor Suppressor ProteinsMouse ModelPathway InteractionsNeoplastic CellGenetic Regulatory ProteinSignal TransductionHomeostasisBaseMalignant NeoplasmsResponseMalignant Breast NeoplasmPre-Clinical ModelCancer Stem CellNeoplasm MetastasisProteinsCells
Grant awards (36)
TGF-betas in breast cancer progression$1,272,987
ZIA · FY2025 · CA · contact PI
Development of TGF-beta antagonists for cancer therapy$848,658
ZIA · FY2025 · CA · contact PI
TGF-betas in breast cancer progression$1,152,383
ZIA · FY2024 · CA · contact PI
Development of TGF-beta antagonists for cancer therapy$768,255
ZIA · FY2024 · CA · contact PI
TGF-betas in breast cancer progression$1,138,499
ZIA · FY2023 · CA · contact PI
Development of TGF-beta antagonists for cancer therapy$758,999
ZIA · FY2023 · CA · contact PI
TGF-betas in breast cancer progression$1,059,250
ZIA · FY2022 · CA · contact PI
Development of TGF-beta antagonists for cancer therapy$706,168
ZIA · FY2022 · CA · contact PI
TGF-betas in breast cancer progression$1,176,097
ZIA · FY2021 · CA · contact PI
Development of TGF-beta antagonists for cancer therapy$784,065
ZIA · FY2021 · CA · contact PI
TGF-betas in breast cancer progression$931,521
ZIA · FY2020 · CA · contact PI
Development of TGF-beta antagonists for cancer therapy$621,015
ZIA · FY2020 · CA · contact PI
TGF-betas in breast cancer progression$881,713
ZIA · FY2019 · CA · contact PI
Development of TGF-beta antagonists for cancer therapy$587,809
ZIA · FY2019 · CA · contact PI
TGF-betas in breast cancer progression$998,687
ZIA · FY2018 · CA · contact PI
Development of TGF-beta antagonists for cancer therapy$428,009
ZIA · FY2018 · CA · contact PI
TGF-betas in breast cancer progression$929,449
ZIA · FY2017 · CA · contact PI
Development of TGF-beta antagonists for cancer therapy$619,633
ZIA · FY2017 · CA · contact PI
Development of TGF-beta antagonists for cancer therapy$858,227
ZIA · FY2016 · CA · contact PI
TGF-betas in breast cancer progression$858,227
ZIA · FY2016 · CA · contact PI
Development of TGF-beta antagonists for cancer therapy$874,425
ZIA · FY2015 · CA · contact PI
TGF-betas in breast cancer progression$874,425
ZIA · FY2015 · CA · contact PI
TGF-betas in breast cancer progression$839,111
ZIA · FY2014 · CA · contact PI
Development of TGF-beta antagonists for cancer therapy$839,111
ZIA · FY2014 · CA · contact PI
TGF-betas in breast cancer progression$817,474
ZIA · FY2013 · CA · contact PI
Development of TGF-beta antagonists for cancer therapy$817,474
ZIA · FY2013 · CA · contact PI
TGF-betas in breast cancer progression$1,218,428
ZIA · FY2012 · CA · contact PI
Development of TGF-beta antagonists for cancer therapy$522,183
ZIA · FY2012 · CA · contact PI
Development of TGF-beta antagonists for cancer therapy$872,836
ZIA · FY2011 · CA · contact PI
TGF-betas in breast cancer progression$872,836
ZIA · FY2011 · CA · contact PI
TGF-betas in breast cancer progression$817,677
ZIA · FY2010 · CA · contact PI
Development of TGF-beta antagonists for cancer therapy$817,677
ZIA · FY2010 · CA · contact PI
Development of TGF-beta antagonists for cancer therapy$823,023
ZIA · FY2009 · CA · contact PI
TGF-betas in breast cancer progression$548,681
ZIA · FY2009 · CA · contact PI
TGF-betas in breast cancer progression$755,487
Z01 · FY2008 · CA · contact PI
Development of TGF-beta antagonists for cancer therapy$503,658
Z01 · FY2008 · CA · contact PI